Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more) Sego Intersects 100 M of 0.626 gpt Gold, Including 24.37 M of 0.958 gpt Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Galectin Therapeutics Inc GALT

Healthcare Biotechnology
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2... see more

Recent & Breaking News (NDAQ:GALT)

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

GlobeNewswire March 31, 2026

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

GlobeNewswire March 17, 2026

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

GlobeNewswire February 26, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 26, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 25, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 24, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

GlobeNewswire January 20, 2026

Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud

Newsfile January 19, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

ACCESS Newswire January 18, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

ACCESS Newswire January 17, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 16, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Shareholders to Reach Out

ACCESS Newswire January 14, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 14, 2026

Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors

Newsfile January 14, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

GlobeNewswire January 13, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Shareholders to Learn More About the Investigation

ACCESS Newswire January 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 12, 2026

Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

ACCESS Newswire January 12, 2026

Podcasts